SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?


To: Ian@SI who wrote (20274)6/14/2006 3:54:52 PM
From: rkrw  Read Replies (1) | Respond to of 52153
 
I'm leaning on your side. Pfizer will just raise their prices to make up for any small decline in rx. So I'd predict flat to plus a few % sales on a dollar basis. Maybe a low single digit decline on an rx basis.

btw, if I were an insurer, heck yeah, I'd push zocor generics and up the copays for lipitor. Squeeze out $11B in costs that can be shifted over to those biotech drugs we invest in :-)